OrthoPediatrics (KIDS) COO/CFO granted shares, sells stock for taxes

Rhea-AI Filing Summary

OrthoPediatrics Corp executive Fred Hite, the COO and CFO, reported both a stock grant and a related share sale. On March 15, 2026, he acquired 77,405 shares of Common Stock as a grant at $0.00 per share. On March 16, 2026, he sold 12,993 shares of Common Stock at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares.

After these transactions, Hite directly owned 277,477 shares of OrthoPediatrics Common Stock, which the disclosure states includes restricted stock awards totaling 197,765 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hite Fred

(Last) (First) (Middle)

C/O ORTHOPEDIATRICS CORP.

2850 FRONTIER DRIVE

(Street)

WARSAW IN 46582

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORTHOPEDIATRICS CORP [ KIDS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		A		77,405	A	$0	290,470	D
Common Stock	03/16/2026		S		12,993(1)	D	$17.25	277,477(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy tax withholding obligations upon vesting of restricted shares.

2. Includes restricted stock awards totaling 197,765 shares.

Remarks:

	/s/ Daniel J. Gerritzen, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did OrthoPediatrics (KIDS) COO/CFO Fred Hite report?

Fred Hite reported a stock grant and a related sale. He received 77,405 OrthoPediatrics Common Stock shares as a grant, then sold 12,993 shares at $17.25 each to cover tax withholding on vested restricted stock.

How many OrthoPediatrics (KIDS) shares does Fred Hite hold after this Form 4?

After the reported transactions, Fred Hite directly owned 277,477 OrthoPediatrics Common Stock shares. The filing notes this amount includes restricted stock awards totaling 197,765 shares, reflecting both vested and unvested equity-based compensation.

Was the OrthoPediatrics (KIDS) insider sale by Fred Hite a discretionary sale?

The sale was disclosed as tax-related. The footnote explains the 12,993 OrthoPediatrics shares sold at $17.25 were to satisfy tax withholding obligations arising from the vesting of restricted shares, rather than a standalone discretionary open-market liquidation.

What was the size of Fred Hite’s OrthoPediatrics (KIDS) stock grant?

Fred Hite received a grant of 77,405 OrthoPediatrics Common Stock shares at $0.00 per share. This non-cash award increased his direct holdings before the subsequent sale of 12,993 shares for tax withholding linked to restricted stock vesting.

What portion of Fred Hite’s OrthoPediatrics (KIDS) holdings are restricted stock awards?

The disclosure states that Hite’s 277,477 directly held OrthoPediatrics shares include 197,765 restricted stock awards. These restricted shares typically vest over time or upon conditions, forming a major component of his equity-based compensation.